BCDA BioCardia, Inc.

NASDAQ
$0.79

BioCardia, Inc. (BCDA) is expected to report earnings on February 11, 2027, after the market close. The consensus earnings estimate is a loss of $0.17 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.7% since its last earnings release on November 12, 2026.

BioCardia Beat Consensus Estimates
Thursday, November 12, 2026 · 4:19 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 4:05 PM ET
Earnings Whisper
-
vs ($0.17)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.81

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About BioCardia, Inc.

BioCardia, Inc. is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived mononuclear cell therapy for cardiovascular indications, and the NK1R+ allogeneic bone marrow derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.